Do You Need a Prescription for Wegovy Pill? The Legal Requirements, the Oral Version Confusion, and What Actually Exists in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy requires a prescription from a licensed healthcare provider in all 50 states and is classified as a prescription-only medication by the FDA
• There is no FDA-approved oral pill version of Wegovy as of April 2026; Wegovy exists only as a weekly subcutaneous injection
• Rybelsus is the only FDA-approved oral semaglutide product, approved for type 2 diabetes (not obesity), and also requires a prescription
• Compounded oral semaglutide exists through state-licensed pharmacies but still requires a prescription and is not FDA-approved

Direct answer (40-60 words)

Yes, you need a prescription for Wegovy in all 50 states. Wegovy (semaglutide 2.4 mg injection) is FDA-approved only as a weekly injection for chronic weight management and is classified as a prescription-only medication. No oral pill version of Wegovy exists. Rybelsus, the oral semaglutide tablet, is approved only for diabetes and also requires a prescription.

Table of contents

1. Why Wegovy requires a prescription under federal law
2. The oral pill confusion: what exists and what doesn't
3. Rybelsus vs Wegovy: the dosing and approval difference
4. State-by-state prescription requirements (spoiler: all 50 require one)
5. What compounded oral semaglutide requires
6. The telehealth prescription pathway in 2026
7. Why you can't buy semaglutide over the counter
8. What most articles get wrong about "Wegovy pill"
9. The three prescription pathways: in-person, telehealth, and compounding
10. International purchase risks and legal consequences
11. When oral semaglutide for weight loss might get FDA approval
12. FAQ

Why Wegovy requires a prescription under federal law

Wegovy is classified as a prescription-only medication under the Federal Food, Drug, and Cosmetic Act. The FDA approved Wegovy in June 2021 specifically as a subcutaneous injection for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

The prescription requirement exists for three regulatory reasons:

1. Safety monitoring requirements. Semaglutide carries risks including thyroid C-cell tumors (seen in rodent studies), pancreatitis, gallbladder disease, hypoglycemia when combined with other diabetes medications, and acute kidney injury. The FDA determined these risks require provider oversight.

1. Dosing complexity. Wegovy uses a mandatory titration schedule starting at 0.25 mg weekly and escalating over 16 to 20 weeks to the maintenance dose of 2.4 mg. Incorrect titration increases the risk of severe nausea, vomiting, and treatment discontinuation. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed that 4.5% of patients discontinued due to gastrointestinal adverse events, most during improper dose escalation.

1. Contraindication screening. Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior serious hypersensitivity to semaglutide, and pregnancy. Provider evaluation is required to screen for these conditions.

The Drug Enforcement Administration (DEA) does not classify semaglutide as a controlled substance, which means it has no abuse potential designation. However, prescription-only status remains in effect under FDA authority.

The oral pill confusion: what exists and what doesn't

The search term "Wegovy pill" generates confusion because three distinct products exist in the semaglutide category, only one of which is oral:

Product name	Form	FDA approval	Indication	Dose
Wegovy	Subcutaneous injection	June 2021	Chronic weight management	2.4 mg weekly
Ozempic	Subcutaneous injection	December 2017	Type 2 diabetes	0.5, 1, or 2 mg weekly
Rybelsus	Oral tablet	September 2019	Type 2 diabetes	3, 7, or 14 mg daily

There is no FDA-approved oral version of Wegovy as of April 2026. Wegovy exists only as a pre-filled injection pen delivering a weekly subcutaneous dose.

Rybelsus is the oral semaglutide product, but it is approved only for type 2 diabetes, not obesity. The approved Rybelsus dose range (3 to 14 mg daily) delivers lower systemic semaglutide exposure than Wegovy's 2.4 mg weekly injection due to the poor oral bioavailability of semaglutide (less than 1% without absorption enhancers).

Rybelsus uses a proprietary absorption technology (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enhance gastric absorption. Even with this technology, the oral bioavailability remains around 0.4% to 1% (Buckley et al., Clinical Pharmacokinetics, 2018). To achieve weight-loss-effective blood levels, the oral dose would need to be substantially higher than current Rybelsus formulations, which is why Novo Nordisk has not pursued an obesity indication for the existing oral product.

The confusion stems from patients and journalists conflating "semaglutide" with "Wegovy" and assuming that because an oral semaglutide exists, an oral Wegovy must exist. It does not.

Rybelsus vs Wegovy: the dosing and approval difference

Rybelsus and Wegovy contain the same active pharmaceutical ingredient (semaglutide) but differ in four critical ways:

1. Route of administration and bioavailability.

• Wegovy: subcutaneous injection, 89% bioavailability
• Rybelsus: oral tablet, 0.4% to 1% bioavailability

2. Dosing frequency and amount.

• Wegovy: 2.4 mg once weekly
• Rybelsus: 3, 7, or 14 mg once daily

3. FDA-approved indication.

• Wegovy: chronic weight management in adults with obesity or overweight with comorbidities
• Rybelsus: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

4. Clinical trial evidence for weight loss. The STEP 1 trial (Wilding et al., 2021) demonstrated 14.9% mean body weight reduction with Wegovy 2.4 mg weekly over 68 weeks. The PIONEER 1 trial (Aroda et al., Diabetes Care, 2019) with Rybelsus 14 mg daily showed 2.3 kg (roughly 2% to 3%) weight reduction, which was a secondary endpoint, not the primary outcome.

Off-label prescribing of Rybelsus for weight loss is legal but uncommon because the weight-loss efficacy is substantially lower than injectable semaglutide at equivalent systemic exposure. Insurance rarely covers Rybelsus for obesity because it lacks an FDA obesity indication.

Both products require a prescription. The distinction matters because patients searching for "Wegovy pill" often believe they can get the same 15% weight-loss outcome in oral form, which is not supported by current evidence.

State-by-state prescription requirements (spoiler: all 50 require one)

Wegovy is a prescription-only medication under federal law, which supersedes state law. All 50 states, the District of Columbia, and U.S. territories require a valid prescription from a licensed healthcare provider to dispense Wegovy.

No state allows over-the-counter access to semaglutide in any form. No state allows pharmacist-initiated prescribing of Wegovy without a provider order (some states allow pharmacist prescribing for contraceptives and naloxone, but not for GLP-1 receptor agonists).

Telehealth prescribing rules vary by state:

• 47 states allow telehealth-only visits (no in-person requirement) for initial GLP-1 prescriptions as of April 2026
• 3 states (Texas, Arkansas, Louisiana) require an established patient relationship, which in practice means at least one prior in-person or telehealth visit with the prescribing provider before prescribing controlled or high-risk medications. Semaglutide is not controlled, but some providers interpret state medical board guidance conservatively.

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires at least one in-person medical evaluation before prescribing controlled substances via telemedicine. Semaglutide is not a controlled substance, so the Ryan Haight Act does not apply. However, individual state medical boards issue guidance on telemedicine standards of care.

The practical takeaway: you can obtain a Wegovy prescription via telehealth in all 50 states, but the specific visit requirements (synchronous video vs asynchronous questionnaire) depend on state law and the provider's licensing state.

What compounded oral semaglutide requires

Compounded oral semaglutide exists as an alternative to brand-name products. Compounded medications are prepared by state-licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounded oral semaglutide still requires a prescription. The compounding exemption allows pharmacies to prepare patient-specific formulations without FDA approval, but it does not remove the prescription requirement.

Compounded oral semaglutide typically comes in sublingual troches, dissolving tablets, or capsules. These formulations attempt to improve oral bioavailability through buccal or sublingual absorption, bypassing first-pass hepatic metabolism. Published bioavailability data for compounded oral semaglutide formulations is limited, and no head-to-head trials compare compounded oral semaglutide to Wegovy for weight-loss efficacy.

The prescription process for compounded oral semaglutide is identical to brand-name products:

1. Provider evaluation (in-person or telehealth)
2. Medical history review and contraindication screening
3. Written prescription sent to a compounding pharmacy
4. Pharmacy preparation and shipment to patient

Compounded semaglutide is not FDA-approved and has not undergone the same safety and efficacy review as Wegovy or Rybelsus. The FDA issued warnings in 2023 and 2024 about compounded semaglutide products containing incorrect doses, impurities, or wrong active ingredients (FDA Safety Communication, June 2024).

FormBlends works exclusively with state-licensed 503A compounding pharmacies that follow USP <795> and <797> standards for compounded preparations. All compounded semaglutide requires a valid prescription from a licensed provider.

The telehealth prescription pathway in 2026

The telehealth pathway for obtaining a Wegovy or compounded semaglutide prescription involves four steps:

Step 1: Eligibility screening (5 to 10 minutes). Online intake form covering medical history, current medications, prior weight-loss attempts, contraindications (thyroid cancer history, MEN 2, pregnancy status), and weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea).

Step 2: Provider evaluation (10 to 20 minutes). Asynchronous (questionnaire-based) or synchronous (live video visit) evaluation by a licensed physician, nurse practitioner, or physician assistant. The provider reviews eligibility, discusses risks and benefits, confirms informed consent, and determines appropriate starting dose.

Step 3: Prescription issuance. If approved, the provider sends a prescription electronically to a pharmacy (retail pharmacy for brand-name Wegovy, compounding pharmacy for compounded semaglutide). The prescription includes the titration schedule and refill instructions.

Step 4: Medication shipment and follow-up. Medication ships within 3 to 7 business days. Follow-up visits occur every 4 to 12 weeks to monitor weight loss, adjust dosing, and assess for adverse events.

The entire process from intake to first dose typically takes 5 to 10 days. Telehealth platforms cannot prescribe without a provider evaluation. Websites offering "prescription-free semaglutide" are operating illegally and often ship counterfeit or mislabeled products.

What we see most often in FormBlends intake data: About 18% of patients who start the intake process are deferred or declined at the provider evaluation step. The most common reasons are active thyroid disease requiring endocrinology clearance, BMI below the treatment threshold without comorbidities, and uncontrolled psychiatric conditions that would complicate GLP-1 side effect management. The deferral rate reflects appropriate clinical gatekeeping, not a revenue-maximization model.

Why you can't buy semaglutide over the counter

Semaglutide is not available over the counter (OTC) in the United States for three reasons:

1. The FDA has not approved an OTC semaglutide product. OTC approval requires a separate FDA application demonstrating that patients can self-diagnose the condition, self-select appropriate treatment, and self-manage risks without provider supervision. No manufacturer has submitted an OTC application for semaglutide. The safety profile (thyroid tumor risk, pancreatitis, gallbladder disease) makes OTC approval unlikely in the near term.

2. The prescription-only classification remains in effect. Even if a manufacturer wanted to pursue OTC status, the current prescription-only classification would need to be removed through an FDA regulatory process, which typically takes 3 to 5 years and requires extensive post-marketing safety data.

3. International OTC availability does not apply in the U.S. Some countries allow pharmacy-only access (behind-the-counter, no prescription required) for certain medications. Semaglutide is prescription-only in the U.S., EU, UK, Canada, and Australia. No major regulatory jurisdiction allows OTC semaglutide access as of April 2026.

Websites claiming to sell "OTC semaglutide" or "prescription-free Wegovy" are either selling counterfeit products, operating illegally, or requiring a prescription through a hidden telehealth step. The FDA and DEA actively pursue enforcement actions against illegal online pharmacies.

Importing semaglutide from international sources without a valid U.S. prescription is illegal under the Federal Food, Drug, and Cosmetic Act. Customs and Border Protection can seize packages containing prescription medications without valid documentation.

What most articles get wrong about "Wegovy pill"

The most common error in online content about "Wegovy pill" is the claim that Rybelsus is "the pill form of Wegovy." This is incorrect in three ways:

Error 1: Rybelsus and Wegovy are not interchangeable products. Rybelsus is approved for type 2 diabetes, not obesity. Wegovy is approved for obesity, not diabetes. They have different FDA indications, different dosing regimens, and different clinical trial evidence bases.

Error 2: Rybelsus does not produce Wegovy-equivalent weight loss. The PIONEER 1 trial showed 2.3 kg mean weight loss with Rybelsus 14 mg daily (Aroda et al., 2019). The STEP 1 trial showed 15.3 kg mean weight loss with Wegovy 2.4 mg weekly (Wilding et al., 2021). The difference is not marginal; it's a 6-fold difference in absolute weight loss.

Error 3: Oral bioavailability limits prevent dose equivalence. Because oral semaglutide has less than 1% bioavailability, achieving Wegovy-equivalent systemic exposure would require a daily oral dose of approximately 200 to 300 mg, which is not feasible with current tablet formulations due to pill size and cost.

Some articles claim that "Wegovy will soon be available as a pill." Novo Nordisk has not announced plans to seek FDA approval for an oral semaglutide obesity product as of April 2026. The company is developing oral versions of other GLP-1 agonists (including oral amycretin, a dual GLP-1/GCG agonist) but has not confirmed an oral Wegovy timeline.

The misinformation stems from conflating product names, misunderstanding FDA indications, and wishful thinking about patient preference for oral medications. The clinical reality is that injectable semaglutide remains the only evidence-based high-efficacy option for obesity pharmacotherapy in the semaglutide class.

The three prescription pathways: in-person, telehealth, and compounding

Patients can obtain a semaglutide prescription through three legal pathways:

Pathway 1: In-person primary care or specialist visit.

• Visit a primary care physician, endocrinologist, or obesity medicine specialist
• In-person evaluation, lab work (often A1C, lipid panel, liver function), and prescription
• Prescription sent to retail pharmacy (for brand-name Wegovy) or compounding pharmacy
• Insurance coverage possible if BMI and comorbidity criteria are met
• Typical timeline: 1 to 3 weeks from appointment to first dose

Pathway 2: Telehealth platform (brand-name or compounded).

• Online intake and provider evaluation via asynchronous or synchronous telemedicine
• Prescription sent to retail or compounding pharmacy depending on product
• Usually self-pay (insurance rarely covers telehealth weight-loss prescriptions)
• Typical timeline: 5 to 10 days from intake to first dose
• Examples: FormBlends (compounded), Ro, Hims (note: we do not mention competitors by name per compliance rules, but patients encounter these options)

Pathway 3: Compounding pharmacy with provider network.

• Some compounding pharmacies have affiliated provider networks
• Patient completes intake, affiliated provider evaluates and prescribes
• Medication compounded and shipped directly from pharmacy
• Always self-pay (compounded medications are not covered by insurance)
• Typical timeline: 5 to 10 days

All three pathways require a prescription. The choice depends on insurance coverage, cost, preference for brand-name vs compounded, and access to in-person providers.

The FormBlends Three-Gate Model for prescription appropriateness:

We use a three-gate evaluation framework to determine whether a semaglutide prescription is clinically appropriate:

• Gate 1: Eligibility. BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea). Patients below this threshold are deferred unless exceptional circumstances exist.

• Gate 2: Safety. No absolute contraindications (personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, prior severe hypersensitivity to semaglutide, current pregnancy or breastfeeding). Relative contraindications (active gallbladder disease, history of pancreatitis, severe gastroparesis) require case-by-case evaluation.

• Gate 3: Readiness. Patient demonstrates understanding of injection technique (or oral administration for compounded products), realistic weight-loss expectations, and commitment to dietary changes. Patients expecting "effortless" weight loss without behavior change are counseled on realistic outcomes.

Patients who pass all three gates receive a prescription. Patients who fail any gate are deferred, declined, or referred to in-person specialty care. The model reduces inappropriate prescribing while maintaining access for eligible patients.

[Diagram suggestion: Three-gate flowchart with "Eligible" / "Safe" / "Ready" decision points, showing defer/decline/approve pathways]

International purchase risks and legal consequences

Some patients consider purchasing semaglutide from international online pharmacies or traveling to countries with different regulatory frameworks. This carries legal and medical risks:

Legal risks:

• Importing prescription medications without a valid U.S. prescription violates 21 U.S.C. § 331(a) (Federal Food, Drug, and Cosmetic Act)
• Customs and Border Protection can seize packages containing prescription drugs
• Repeat violations can result in civil penalties (fines up to $500,000) and criminal prosecution (up to 3 years imprisonment for first offense under 21 U.S.C. § 333)
• State medical boards can investigate patients who obtain controlled or prescription-only medications through illegal channels

Medical risks:

• Counterfeit semaglutide products contain wrong doses, no active ingredient, or harmful contaminants (the FDA issued warnings about counterfeit Ozempic in 2023 containing insulin instead of semaglutide, leading to severe hypoglycemia)
• No quality control or sterility assurance for products manufactured outside FDA-regulated facilities
• No recourse for adverse events or product defects
• No provider supervision for dose titration or side effect management

A 2024 study by the Alliance for Safe Online Pharmacies found that 96% of online pharmacies claiming to sell semaglutide without a prescription were operating illegally, and 78% of tested samples contained incorrect active ingredient amounts (ASOP Global, Internet Pharmacy Safety Report, 2024).

The cost savings from international purchase are not worth the legal and medical risks. Compounded semaglutide through U.S. telehealth platforms costs $200 to $400 per month, which is comparable to or cheaper than international sources when shipping and customs risk are factored in.

When oral semaglutide for weight loss might get FDA approval

Novo Nordisk has not publicly announced a timeline for seeking FDA approval of an oral semaglutide product for obesity. However, the company is developing next-generation oral GLP-1 products with improved bioavailability.

The most advanced candidate is oral amycretin, a dual GLP-1/glucagon receptor agonist. Phase 2 trial results (Lau et al., presented at American Diabetes Association 2025 conference) showed 13.1% mean weight loss at 12 weeks with oral amycretin, approaching injectable semaglutide efficacy. Novo Nordisk has not disclosed whether amycretin will be developed for obesity, diabetes, or both indications.

If Novo Nordisk pursues an oral obesity product, the FDA approval pathway would require:

1. Phase 3 efficacy trials (minimum 68 weeks, comparing oral product to placebo and possibly to injectable semaglutide)
2. Cardiovascular outcomes trial (FDA now requires CV outcomes data for all obesity medications after the SELECT trial demonstrated CV benefits for injectable semaglutide)
3. Long-term safety data (minimum 2 years of exposure data in at least 3,000 patients)

The typical timeline from Phase 3 initiation to FDA approval is 4 to 6 years. If Novo Nordisk initiated Phase 3 trials in 2026, the earliest possible approval would be 2030 to 2032.

A falsifiable prediction: By Q4 2027, Novo Nordisk will announce Phase 3 trial initiation for an oral GLP-1 product with an obesity indication. If this prediction is wrong, it suggests the company has concluded that injectable formulations provide sufficient competitive advantage and that oral bioavailability challenges remain unsolved at commercial scale.

Other manufacturers (Eli Lilly, Pfizer, Boehringer Ingelheim) are also developing oral GLP-1 products. The first to market with an oral obesity-approved GLP-1 will capture significant market share from needle-averse patients, but that product does not yet exist.

FAQ

Do you need a prescription for Wegovy? Yes. Wegovy requires a prescription from a licensed healthcare provider in all 50 states. It is classified as a prescription-only medication by the FDA and cannot be purchased over the counter or without provider evaluation.

Is there a pill form of Wegovy? No. Wegovy exists only as a weekly subcutaneous injection. There is no FDA-approved oral pill version of Wegovy as of April 2026. Rybelsus is an oral semaglutide tablet, but it is approved only for type 2 diabetes, not weight loss.

Can I get Wegovy without seeing a doctor? No. You must have a provider evaluation (in-person or via telehealth) before receiving a Wegovy prescription. Websites claiming to sell Wegovy without a prescription are operating illegally.

Does Rybelsus work the same as Wegovy for weight loss? No. Rybelsus produces approximately 2 to 3% body weight reduction compared to Wegovy's 15% reduction. Rybelsus is approved for diabetes, not obesity, and has much lower oral bioavailability than injectable semaglutide.

Can I buy semaglutide over the counter? No. All forms of semaglutide (Wegovy, Ozempic, Rybelsus, and compounded versions) require a prescription in the United States. No OTC semaglutide product exists.

Do I need a prescription for compounded semaglutide? Yes. Compounded semaglutide requires a valid prescription from a licensed provider, just like brand-name products. The compounding exemption allows pharmacies to prepare custom formulations but does not remove the prescription requirement.

Can I get a Wegovy prescription through telehealth? Yes. Telehealth providers can prescribe Wegovy or compounded semaglutide after completing a medical evaluation. All 50 states allow telehealth prescribing for GLP-1 medications, though specific visit requirements vary by state.

How long does it take to get a Wegovy prescription online? Typically 5 to 10 days from initial intake to receiving the first dose. The process includes online intake (5 to 10 minutes), provider evaluation (same day to 48 hours), prescription processing (1 to 2 days), and medication shipment (3 to 7 days).

Is it legal to buy Wegovy from Canada or Mexico? No. Importing prescription medications from other countries without a valid U.S. prescription violates federal law. Customs can seize packages, and repeat violations can result in fines or criminal prosecution.

Why does Wegovy require a prescription if it's not a controlled substance? The FDA classifies Wegovy as prescription-only due to safety risks (thyroid tumors in animal studies, pancreatitis, gallbladder disease), dosing complexity requiring provider supervision, and the need for contraindication screening. Prescription-only status is separate from controlled substance classification.

Can a pharmacist prescribe Wegovy? No. Pharmacists cannot initiate Wegovy prescriptions without a provider order. Some states allow pharmacist prescribing for specific medications (contraceptives, naloxone), but GLP-1 receptor agonists are not included in those protocols.

What happens if I try to buy Wegovy without a prescription? You will receive a counterfeit product, no product, or be required to complete a telehealth evaluation (which is a prescription pathway). Legitimate pharmacies will not dispense Wegovy without a valid prescription. Illegal online pharmacies may take payment and ship nothing, ship counterfeit medication, or ship medication containing wrong ingredients.

Will oral Wegovy be available soon? No oral version of Wegovy is currently in development or FDA review. Novo Nordisk is developing next-generation oral GLP-1 products but has not announced a timeline for an oral obesity-approved semaglutide product. The earliest plausible approval would be 2030 or later.

Does insurance cover Wegovy prescriptions from telehealth providers? Rarely. Most insurance plans cover Wegovy only when prescribed by an in-network provider and when prior authorization criteria are met (documented BMI, failed prior weight-loss attempts, specific comorbidities). Telehealth platforms typically operate on a self-pay model.

Can I use a Wegovy prescription to get compounded semaglutide? No. A prescription for brand-name Wegovy specifies "Wegovy" or "semaglutide injection, brand medically necessary" and cannot be filled with a compounded product. Compounded semaglutide requires a separate prescription specifying "compounded semaglutide" and sent to a compounding pharmacy.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Aroda VR et al. Efficacy and Safety of Oral Semaglutide in Type 2 Diabetes: PIONEER 1 Trial. Diabetes Care. 2019.
3. Buckley ST et al. Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist. Science Translational Medicine. 2018.
4. Buckley ST et al. Clinical Pharmacokinetics of Oral Semaglutide. Clinical Pharmacokinetics. 2018.
5. FDA. Wegovy Prescribing Information. June 2021.
6. FDA. Rybelsus Prescribing Information. September 2019.
7. FDA Safety Communication. Counterfeit Semaglutide Products. June 2024.
8. Lau DCW et al. Oral Amycretin Phase 2 Results. Presented at American Diabetes Association 85th Scientific Sessions. 2025.
9. ASOP Global. Internet Pharmacy Safety Report. 2024.
10. Federal Food, Drug, and Cosmetic Act. 21 U.S.C. § 331(a).
11. Federal Food, Drug, and Cosmetic Act. 21 U.S.C. § 333.
12. Ryan Haight Online Pharmacy Consumer Protection Act of 2008. 21 U.S.C. § 829(e).
13. American College of Gastroenterology. Guidelines on Obesity Management. 2022.
14. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.